| Exec date | Filing date | Company | Role | Signal | Confidence | Shares | % of shares | Under plan? | Amount (USD) |
|---|---|---|---|---|---|---|---|---|---|
| May 23, 2022 | May 25, 2022 | AbbVie Inc. | Chair | Sell | 2.5 | -79,801 | -34.41% | ✓ | $12M |
| May 16, 2022 | May 18, 2022 | AbbVie Inc. | Chair | Sell | 12.5 | -200,000 | -16.32% | ✓ | $30.8M |
| May 6, 2022 | May 10, 2022 | AbbVie Inc. | Chair | Sell | 12.5 | -300,000 | -15.45% | ✓ | $45.3M |
| Feb 25, 2022 | Mar 1, 2022 | AbbVie Inc. | Chair | Sell | 16.3 | -38,857 | -20.35% | ✗ | $5.8M |
| Feb 28, 2021 | Mar 2, 2021 | AbbVie Inc. | Chair | Sell | 17.5 | -29,077 | -21.88% | ✗ | $3.1M |
| Nov 4, 2020 | Nov 6, 2020 | AbbVie Inc. | Chair | Sell | 3.8 | -90,679 | -57.41% | ✓ | $8.5M |
| Feb 28, 2020 | Mar 3, 2020 | AbbVie Inc. | Chair | Sell | 17.5 | -33,492 | -17.49% | ✗ | $2.9M |
| Feb 28, 2019 | Mar 4, 2019 | AbbVie Inc. | Chair | Sell | 17.5 | -26,710 | -18.74% | ✗ | $2.1M |
| Aug 17, 2018 | Aug 21, 2018 | AbbVie Inc. | EVP, R&D and CSO | Sell | 17.5 | -50,000 | -37.80% | ✗ | $4.9M |
| Feb 28, 2018 | Mar 2, 2018 | AbbVie Inc. | EVP, R&D and CSO | Sell | 15.0 | -30,326 | -18.65% | ✓ | $3.6M |
| Nov 10, 2017 | Nov 13, 2017 | AbbVie Inc. | EVP, R&D and CSO | Sell | 15.0 | -25,633 | -18.24% | ✓ | $2.4M |
| Jun 2, 2017 | Jun 5, 2017 | AbbVie Inc. | EVP, R&D and CSO | Sell | 17.5 | -21,576 | -13.31% | ✗ | $1.4M |
| Feb 28, 2017 | Mar 2, 2017 | AbbVie Inc. | EVP, R&D and CSO | Buy | 100.0 | +30,699 | 23.36% | ✗ | $1.9M |